Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.

British journal of haematology - 1 Mar 2004

Paterson Joshua L, Li Zhihua, Wen Xiao-Yan, Masih-Khan Esther, Chang Hong, Pollett Jonathan B, Trudel Suzanne, Stewart A Keith

Abstract excerpt

Dysregulation of fibroblast growth factor receptor 3 (FGFR3) by the translocation t(4;14)(p16;q32) occurs in 15% of multiple myeloma (MM) patients and confers a growth and survival advantage to malignant plasma cells. As FGFR3 is a molecular target, we assessed the therapeutic potential of the FGFR-specific tyrosine kinase inhibitors SU5402 and SU10991 in MM. SU5402 inhibited FGFR3 phosphorylation in vitro and in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mitogen-Activated Protein Kinase 1
Share to Mitogen-Activated Protein Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Myeloma

Share to Pyrroles

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Receptors, Fibroblast Growth Factor

Share to Suppressor of Cytokine Signaling 1 Protein

Share to Suppressor of Cytokine Signaling Proteins

Source

Identifiers

PMID: 14871245
DOI: 10.1111/j.1365-2141.2004.04814.x

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.PMID 14871245Read ↗

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myelomaSemantic proximity Read ↗

The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategiesSemantic proximity Read ↗

Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.Semantic proximity Read ↗

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patientsSemantic proximity Read ↗

Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myelomaSemantic proximity Read ↗

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.Semantic proximity Read ↗

The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression.Semantic proximity Read ↗

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.Semantic proximity Read ↗

MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cellsSemantic proximity Read ↗

A molecular study of the t(4;14) in multiple myeloma.Semantic proximity Read ↗

Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis.Semantic proximity Read ↗

MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.